Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: Phase I results Meeting Abstract
| Authors: | Orlowski, R. Z.; Stewart, K.; Vallone, M.; Molineaux, C.; Kunkel, L.; Gerecitano, J.; O'Connor, O. A. |
| Abstract Title: | Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: Phase I results |
| Meeting Title: | 49th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 110 |
| Issue: | 11 Pt. 1 |
| Meeting Dates: | 2007 Dec 8-11 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2007-11-01 |
| Start Page: | 127A |
| Language: | English |
| ACCESSION: | WOS:000251100800410 |
| PROVIDER: | wos |
| PUBMED: | 18092369 |
| DOI: | 10.1182/blood.V110.11.409.409 |
| Notes: | --- - Meeting Abstract: 409 - Oral Session - 49th Annual Meeting of the American-Society-of-Hematology - DEC 08-11, 2007 - Atlanta, GA - Part 1 - "Source: Wos" |
